GlaxoSmithKline Pharmaceuticals Limited — Board Meeting, 14-02-2025: Outcome of Board Meeting

The Board of Directors of GlaxoSmithKline Pharmaceuticals Limited, during its recent meeting, approved the un-audited standalone and consolidated financial results for the third quarter and nine months. Key highlights include revenue from operations at ₹946.36 Cr for the quarter, and ₹2,757.41 Cr for the nine months. The company's profit for the quarter stood at ₹228.58 Cr, while profit for the nine months was ₹658.92 Cr. Additionally, Mr. Juby Chandy was re-appointed as Whole-time Director & CFO for two years, effective April 1, 2025. A special interim dividend of ₹203.29 Cr was also declared.